Summary
Vertex Pharmaceuticals Inc. presented its 2013 annual report, highlighting significant progress in its core focus area: cystic fibrosis (CF). The company successfully launched and is expanding the reach of KALYDECO (ivacaftor) for CF patients with the G551D mutation. Vertex is actively pursuing label expansions for KALYDECO to include patients with other CFTR gene mutations and is also advancing combination therapies with lumacaftor (VX-809) and ivacaftor for the prevalent F508del mutation, with Phase 3 data expected in mid-2014. However, the company is facing challenges in its Hepatitis C (HCV) business, with INCIVEK revenues declining significantly due to increased competition. Vertex has also recorded substantial intangible asset impairment charges related to its HCV drug candidates, leading to a net loss for the year. Despite these setbacks, Vertex maintains a strong cash position and continues to invest heavily in research and development, particularly in CF, aiming to provide transformative treatments for serious diseases.
Financial Highlights
49 data points| Revenue | $1.21B |
| Cost of Revenue | $88.98M |
| Gross Profit | $1.12B |
| R&D Expenses | $882.10M |
| SG&A Expenses | $356.19M |
| Operating Expenses | $1.82B |
| Operating Income | -$610.01M |
| Net Income | -$445.03M |
| EPS (Basic) | $-1.98 |
| EPS (Diluted) | $-1.98 |
| Shares Outstanding (Basic) | 224.91M |
| Shares Outstanding (Diluted) | 224.91M |
Key Highlights
- 1Vertex Pharmaceuticals achieved significant revenue growth for KALYDECO (ivacaftor) in 2013, its primary CF therapy, and is actively seeking to expand its approved indications.
- 2The company is progressing with Phase 3 clinical trials for the combination of lumacaftor and ivacaftor for the F508del mutation in cystic fibrosis, with expected data in mid-2014 and potential regulatory submissions in the second half of 2014.
- 3The company reported a substantial decline in INCIVEK (telaprevir) revenues, a drug for Hepatitis C, due to increased market competition, leading to a strategic reduction in promotion and support.
- 4Vertex recorded significant intangible asset impairment charges totaling $663.5 million in 2013, primarily related to its HCV drug development candidates VX-222 and VX-135.
- 5The company experienced a net loss of $445.0 million in 2013, a significant increase from the $107.0 million net loss in 2012, largely driven by impairment charges and the decline in INCIVEK sales.
- 6Vertex has a strong cash position with approximately $1.47 billion in cash, cash equivalents, and marketable securities as of December 31, 2013, providing a solid financial foundation for ongoing R&D.
- 7The company is also advancing VX-661, another investigational CFTR corrector, in Phase 2 clinical development for cystic fibrosis.